Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

2019522 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 20, Issue 5, pp. 636-648

Field-Weighted Citation Impact: 30.78